GlassScriptPhysician profile
Donald Carney
NPI 1932104932
$4,064.02
in general payments reported to CMS, 2019-2025
36 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $828 · 2020: $714 · 2021: $917 · 2022: $574 · 2023: $599 · 2024: $249 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,031.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $588.59 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $473.68 | 2020-2023 | Mavyret |
| Amgen INC. | $352.31 | 2019-2024 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $334.92 | 2019-2025 | Enflonsia, Rotateq, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $307.97 | 2019-2025 | Airsupra |
| Pfizer INC. | $303.15 | 2019-2025 | |
| Lilly USA, LLC | $180.71 | 2021-2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.05 | 2020-2022 | |
| Mylan Specialty L.P. | $141.38 | 2019 | |
| Janssen Pharmaceuticals, INC | $138.39 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.65 | 2022-2023 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $115.50 | 2021-2022 | |
| Amarin Pharma, INC. | $105.04 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $89.40 | 2022-2023 | Rexulti, Nuedexta |
| Radius Health, INC. | $83.49 | 2024-2025 | Tymlos |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $73.31 | 2020-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $71.76 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $52.24 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $42.60 | 2019-2022 | |
| Boston Scientific Corporation | $30.89 | 2025 | General - Therapies, Wavewriter Alpha Prime 16 |
| Biohaven Pharmaceutical Holding Company LTD. | $28.22 | 2022 | |
| Philips North America LLC | $26.81 | 2022-2025 | Ecc Solutions |
| Nevro Corp. | $25.36 | 2022 | |
| Astellas Pharma US INC | $23.47 | 2024 | Veozah |
| Cranial Technologies, INC | $21.27 | 2021 | |
| Genentech USA, INC. | $20.94 | 2020 | |
| Dexcom, INC. | $19.30 | 2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $18.88 | 2024 | Omnipod |
| Lundbeck LLC | $16.58 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.79 | 2022 | |
| Sunovion Pharmaceuticals INC. | $15.57 | 2020 | |
| Exact Sciences Corporation | $13.41 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $13.05 | 2021 | |
| Eisai INC. | $12.71 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.81 | 2019 | |
| Sanofi Pasteur INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Carney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.